Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has launched with an oversubscribed $18 million (about €16.2 million) seed financing. The company, a spin-out from Eleven Therapeutics, will use the funding to expand DELiveri®, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types, addressing a major constraint in genetic medicine delivery.

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has launched with an oversubscribed $18 million (about €16.2 million) seed financing. The company, a spin-out from Eleven Therapeutics, will use the funding to expand DELiveri®, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types, addressing a major constraint in genetic medicine delivery.

The challenge of reaching beyond the liver

RNA interference has transformed the treatment of liver-expressed diseases, but reaching tissues beyond the liver remains a key obstacle limiting the broader potential of the modality. DELiveri screens massive-scale combinatorial libraries of candidate ligands, converting cells into molecular radars that detect productive delivery at single-molecule resolution. The resulting high-throughput data are analysed by agentic AI, which decodes the structure-activity relationships and identifies conjugates capable of carrying siRNA into target cells.

Renovascular disease as the first focus

Undecimal is initially applying the platform in renovascular diseases, which pose significant unmet clinical need. The company notes that existing treatments largely address symptoms rather than the underlying aetiological factors. It says targeted siRNA delivery holds the potential to bring digital-like precision to genetic medicines, enabling durable, target-specific silencing of the pathways that drive disease.

“The hard problem in RNAi was never the silencing, it was getting the molecule to the right cell,” said Dr Yaniv Erlich, CEO and co-founder of Undecimal Bio. “Our in-vivo validated DELiveri platform can screen large chemical spaces at an un-
precedented pace, generating massive data for our legions of AI agents to decipher the structure-activity relationship and score the best candidates. We are excited to bring these advances to develop the next generation of siRNA therapeutics for the benefit of patients.”

Investors, governance and collaborations

The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital. The funding will be used to further develop the DELiveri platform, progress Undecimal’s renovascular programmes and expand the team at the company’s laboratories at the Cancer Research UK Cambridge Institute.

The board of directors comprises representatives of 4BIO Capital, IQ Capital and Harel Technologies, together with co-founders Dr Yaniv Erlich and Shaul Ilan, while Verve Ventures joins the board as an observer. Undecimal has also entered several research collaborations with large pharmaceutical companies, which have yet to be disclosed.